SEMAGLUTIDE- REVOLUTIONARY DRUG IN OBESITY MANAGEMENT
Semaglutide is one of the most widely used glucagon-like peptide-1 receptor agonists, initially approved for the treatment of type 2 diabetes and now increasingly utilized for obesity treatment. Its efficacy in weight reduction has led to a surge in popularity; however, concerns regarding its safety profile and potential side effects have emerged. This review aims to analyze the mechanism of action, therapeutic efficacy, and potential risks associated with semaglutide use.
Authors
- Anita Warzocha (ORCID: https://orcid.org/0009-0006-9845-4634)
- Anita Krowiak (ORCID: https://orcid.org/0009-0008-0077-0925)
- Maria Jasiewicz (ORCID: https://orcid.org/0009-0008-0718-2528)
- Karolina Krowiak (ORCID: https://orcid.org/0009-0001-6704-0838)
- Magdalena Kowalczyk (ORCID: https://orcid.org/0000-0001-9647-1840)
- Aleksandra Karnaś (ORCID: https://orcid.org/0009-0005-9708-3467)
- Gabriela Majka (ORCID: https://orcid.org/0009-0002-7100-5119)
- Piotr Pitrus (ORCID: https://orcid.org/0009-0006-2168-9187)
- Karol Bednarz (ORCID: https://orcid.org/0000-0001-9196-1621)
- Wiktoria Hander (ORCID: https://orcid.org/0009-0002-3000-9703)
Institutions
- University of Rzeszów (PL)
Publication Details
- Journal
- International Journal of Innovative Technologies in Social Science
- Published
- 2025-09-18
- DOI
- https://doi.org/10.31435/ijitss.3(47).2025.3877
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00